Through intragastric administration, CUR can alleviate psoriasis‐like lesions of mice by decreasing PASI scores, reducing the level of IL‐6, IL‐17A, IL‐22, IL‐23, TNF‐α, and TGF‐β1, promoting the expression of IL‐10. Here, IL22 is linked to psoriasis.